B
Brian J. Nankivell
Researcher at Westmead Hospital
Publications - 136
Citations - 14047
Brian J. Nankivell is an academic researcher from Westmead Hospital. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 47, co-authored 126 publications receiving 12632 citations. Previous affiliations of Brian J. Nankivell include University of Sydney.
Papers
More filters
Journal ArticleDOI
The natural history of chronic allograft nephropathy.
Brian J. Nankivell,Richard Borrows,Caroline L.-S. Fung,Philip J. O'Connell,Richard D. M. Allen,Jeremy R. Chapman +5 more
TL;DR: Chronic allograft nephropathy represents cumulative and incremental damage to nephrons from time-dependent immunologic and nonimmunologic causes, and was irreversible, resulting in declining renal function and graft failure.
Journal ArticleDOI
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
Kim Solez,Robert B. Colvin,Lorraine C. Racusen,Mark Haas,Banu Sis,Michael Mengel,Philip F. Halloran,William M. Baldwin,G. Banfi,A. B. Collins,Fernando G. Cosio,D. S. R. David,Cinthia B. Drachenberg,Gunilla Einecke,Agnes B. Fogo,Ian W. Gibson,Denis Glotz,Samy S. Iskandar,Edward S. Kraus,Evelyne Lerut,Roslyn B. Mannon,Michael J. Mihatsch,Brian J. Nankivell,Volker Nickeleit,John C. Papadimitriou,Parmjeet Randhawa,Heinz Regele,Karine Renaudin,Ian S.D. Roberts,Daniel Serón,Rex Neal Smith,Marialuisa Valente +31 more
TL;DR: Emerging research data led to the establishment of collaborative working groups addressing issues like isolated ‘v’ lesion and incorporation of omics‐technologies, paving the way for future combination of graft biopsy and molecular parameters within the Banff process.
Journal ArticleDOI
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN').
Kim Solez,Robert B. Colvin,Lorraine C. Racusen,Banu Sis,Philip F. Halloran,Patricia E. Birk,Patricia Campbell,Marilia Cascalho,A. B. Collins,Anthony J. Demetris,Cinthia B. Drachenberg,Ian W. Gibson,Paul C. Grimm,Mark Haas,Evelyne Lerut,Helen Liapis,Roslyn B. Mannon,P. B. Marcus,Michael Mengel,Michael J. Mihatsch,Brian J. Nankivell,Volker Nickeleit,John C. Papadimitriou,Jeffrey L. Platt,Parmjeet Randhawa,Ian Roberts,L. Salinas-Madriga,Daniel R. Salomon,Daniel Serón,M. Sheaff,Jan J. Weening +30 more
TL;DR: The 8th Banff Conference on Allograft Pathology was held in Edmonton, Canada, 15–21 July 2005, and major outcomes included the elimination of the non‐specific term ‘chronic allograft nephropathy’ (CAN) and the recognition of the entity of chronic antibody‐mediated rejection.
Journal ArticleDOI
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
Mark Haas,Alexandre Loupy,Carmen Lefaucheur,Candice Roufosse,Denis Glotz,Daniel Serón,Brian J. Nankivell,Philip F. Halloran,Robert B. Colvin,Enver Akalin,Nada Alachkar,Serena M. Bagnasco,Yassine Bouatou,Yassine Bouatou,Jan U. Becker,Lynn D. Cornell,J.-P. Duong Van Huyen,Ian W. Gibson,Edward S. Kraus,Roslyn B. Mannon,Maarten Naesens,Volker Nickeleit,Peter Nickerson,Dorry L. Segev,Harsharan K. Singh,Mark D. Stegall,P. Randhawa,Lorraine C. Racusen,Kim Solez,Michael Mengel +29 more
TL;DR: The Banff ABMR criteria are updated and paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next‐generation clinical trials.
Journal ArticleDOI
Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups
Banu Sis,Michael Mengel,Mark Haas,Robert B. Colvin,Philip F. Halloran,Lorraine C. Racusen,Kim Solez,William M. Baldwin,Erika Bracamonte,V. Broecker,Fernando G. Cosio,Anthony J. Demetris,Cinthia B. Drachenberg,Gunilla Einecke,James M. Gloor,Denis Glotz,Edward S. Kraus,Christophe Legendre,Helen Liapis,Roslyn B. Mannon,Brian J. Nankivell,Volker Nickeleit,John C. Papadimitriou,Parmjeet Randhawa,Heinz Regele,Karine Renaudin,E. R. Rodriguez,Daniel Serón,Surya V. Seshan,Manikkam Suthanthiran,Barbara A. Wasowska,Andrea A. Zachary,A. Zeevi +32 more
TL;DR: The willingness of the Banff process to adapt continuously in response to new research and improve potential weaknesses, led to the implementation of six working groups on the following areas: isolated v‐lesion, fibrosis scoring, glomerular lesions, molecular pathology, polyomavirus nephropathy and quality assurance.